Can Human Papillomavirus DNA Testing Substitute for Cytology in the Detection of High-Grade Cervical Lesions?
|
|
- Curtis Cooper
- 5 years ago
- Views:
Transcription
1 Can Human Papillomavirus DNA Testing Substitute for Cytology in the Detection of High-Grade Cervical Lesions? Kyung-Ju Lee, MD; Jae-Kwan Lee, MD; Ho-Suk Saw, MD, PhD Context. High-risk human papillomaviruses (HPVs) are causal factors of cervical carcinomas. Objective. To evaluate the sensitivity and efficiency of HPV DNA testing in comparison with conventional cytology for detection of cervical intraepithelial neoplasia (CIN) and cancer. Design. Both testing procedures were administered to 593 women, aged 4 to 88 years (average, 4.7 years), who were referred for abnormal cytology from January through December at Korea University Guro Hospital (Seoul, Korea). After histologic confirmation by either colposcopically directed biopsy or endocervical curettage, the efficiency of the detection methods for high-grade cervical lesion was evaluated for the following 3 data sets: HPV DNA testing, conventional cytology, and the tests combined. Results. The sensitivity, specificity, and positive predictive, and negative predictive values for the detection of CIN or higher were 9.4%, 5.4%, 49.3%, and 93.% for HPV DNA testing; 76.3%, 65.8%, 5.8%, and 84.7% for cytology; and 97.8%, 36.7%, 49.%, and 97.3% for the combined tests. Among the 5 patients diagnosed with CIN or CIN 3, 37 patients (9.7%) were HPV positive, 6 patients (76.8%) were proven to have abnormal cytology, and 47 patients (97.6%) were positive for either HPV DNA testing or cytology. The sensitivity values for HPV DNA testing and cytology were 97.9% (46/ 47) and 74.5% (35/47), respectively, for invasive cervical cancer detection, and the combined tests showed % (47/47) sensitivity. Depending on the patient s age and the grade of the cervical lesion, HPV DNA testing proved to be significantly more sensitive than cytology for the primary detection of cervical abnormalities (P.). Conclusion. Human papillomavirus DNA testing for the detection of high-grade cervical lesions was more sensitive than cytology alone. In addition, the screening sensitivity can be further improved by combining cytology with HPV DNA testing. This approach is especially beneficial in detecting cancer precursors in women older than 6 years. (Arch Pathol Lab Med. 4;8:98 3) Cervical cancer screening with the Papanicolaou (Pap) test was introduced in the late 95s in Korea. Cervical cancer has been reported to be the most common gynecologic malignancy; approximately 5 cases of cervical cancer are registered in the gynecologic cancer registry program in Korea each year. Although the rate of cervical cancer has declined significantly during the past several years, it remains one of the most common female cancers in developing countries owing to the appreciable Accepted for publication October 7, 3. From the Department of Obstetrics and Gynecology, College of Medicine, Pochon CHA University, CHA General Hospital, Seoul, Korea (Dr K.-J. Lee); and Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Korea University, School of Medicine, Seoul, Korea (Drs J.-K. Lee and Saw). Presented as a poster at the Ninth Biennial Meeting of the International Gynecologic Cancer Society, Seoul, Korea, October 4,. The authors have no relevant financial interest in the products or companies described in this article. Reprints: Ho-Suk Saw, MD, PhD, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Korea University School of Medicine, Guro Hospital, Guro-Dong, Guro-Gu, Seoul, Korea 5-73 ( sawhs@korea.ac.kr). false-negative rate and inconsistent accuracy of the Pap test. Human papillomavirus (HPV) infection has been established as the major risk factor for cervical intraepithelial neoplasia (CIN) and for cervical cancer. 3 7 Human papillomavirus DNA testing relies on the detection of viral DNA in exfoliated cell specimens. The hybrid capture test for HPV DNA has proven analytic sensitivity and has been shown to be accurate and reproducible. Several studies have considered HPV DNA testing as a second-level procedure for women who have borderline or mild cytologic abnormalities. 4,8 On the other hand, Clavel et al 9 suggested HPV DNA testing as a primary screening tool for detection of high-grade intraepithelial lesions. Hence, the purpose of this study was to evaluate the role of HPV DNA testing with Hybrid Capture (HC; Digene Corporation, Inc, Gaithersburg, Md) in detecting CIN and cancer in comparison to conventional cervical cytology. MATERIALS AND METHODS We investigated 673 women who were referred to Korea University Guro Hospital, Seoul, for abnormal cytologic findings during the 4-month period from January to December. We excluded patients who had had recent surgical treatment for their cytologic abnormalities. We also carefully exam- 98 Arch Pathol Lab Med Vol 8, March 4 HPV DNA Testing for Cervical Lesions Lee et al
2 Table. Tests HPV DNA test Positive Negative Cytology Abnormal Normal Combined tests Abnormal and/or positive Normal and negative * P.. Screening Utility of Human Papillomavirus (HPV) DNA Test, Cytology, and Their Combination Confirmed by Biopsy CIN CIN * 5 47* 94 4 Sensitivity, % Specificity, % Positive Predictive Value, % Negative Predictive Value, % 9.4* * Table. HPV-DNA test positive HPV-DNA test negative Cytology positive Cytology negative HPV-DNA test positive and/or cytology positive HPV-DNA test negative and cytology negative Detection of Cervical Intraepithelial Neoplasia (CIN), 3, and Type of Cervical Cancer CIN, 3 (Sensitivity, %) 37 (9.7) 4 6 (76.8) (97.6) 4 Cervical Cancer ABC ACA AdSq GCC SCC Total (Sensitivity, %) 46 (97.9) 35 (74.5) 47 () * HPV indicates human papillomavirus; ABC, adenoid basal cell carcinoma; ACA, adenocarcinoma; AdSq, adenosquamous cell carcinoma; GCC, glassy cell carcinoma; and SCC, squamous cell carcinoma. ined the cytologic results before referring these patients to our hospital to avoid possible interference on Pap test results from the various testing intervals. All the patients were informed of the purpose of this study and agreed to participate. They were offered the opportunity to be tested with HPV DNA testing with HC in addition to conventional cytology. Conventional cytology was obtained using cervical scrapes with the New-PAP brush (Young Medical Co, Seoul, Korea), and hospital pathologists inspected these materials blindly. Human papillomavirus DNA testing was performed using the New-PAP brush from the commercial HC system. All scrapes were analyzed for the presence of high-risk HPV types 6, 8, 3, 33, 35, 39, 45, 5, 5, 56, 58, 59, and 68; the positive threshold was set at. pg ml of HPV DNA. This enzyme-linked immunosorbent assay is based on a sandwich hybridization followed by a nonradioactive alkaline phosphatase reaction with chemoluminescence in microplates. All patients underwent colposcopic examinations. The results were confirmed either by biopsy or endocervical curettage within the next few days or weeks. Endocervical curettage was performed only when no cervical lesion had been detected under colposcopic examination. The Bethesda System was used for the classification of cytologic studies. An abnormal Pap test was defined as atypical squamous cells of undetermined significance (ASCUS) and/or atypical glandular cells of undetermined significance (AGUS) or higher,, and positive biopsy was defined as CIN grade or higher. Here, we chose histologically proven CIN or higher as the primary endpoint of detection tests, because CIN regresses more spontaneously than CIN. 3,4 To compare the screening performance between the laboratory tests, we calculated the sensitivity, specificity, and predictive values from the preliminary data. These results were put into a table showing both positive and negative results. Finally, the screening performance of each laboratory test was assessed by the McNemar test with the statistical significance set at P.5. RESULTS Of the original 673 women, 73 women who received only test or who did not undergo colposcopically directed biopsy or endocervical curettage were excluded from this study. Seven women who had ovarian cancer or endometrial cancer were also excluded. The remaining 593 women were eligible for this study. Their ages ranged from 4 to 88 years, with an average of 4.7 years. They all received detection tests of HPV DNA testing and cytology. Using either colposcopically directed biopsy or endocervical curettage results as the reference data for the existence of each individual s CIN or higher, the efficiency levels of the detection methods were measured separately for HPV DNA testing, conventional cytology, and the combined tests. Primary results are shown in Table. The sensitivity, specificity, false-positive rate, and false-negative rate were calculated for each test. In our results, the sensitivity and negative predictive values of HPV DNA testing was 9.4% and 93.%, respectively, and these same values for cytology were 76.3% and 84.7%, respectively, in CIN, 3 and cancer, which indicates that the positive diagnosis of the HPV DNA testing was more sensitive than conventional cytology (P.). When the tests were combined, the sensitivity was 97.8% with a negative predictive value of 97.3%. Human papillomavirus DNA testing was essential in suspecting high-grade lesions of the cervix and was more accurate than cytology alone in diagnosing CIN or higher. The results for detecting CIN and CIN 3 with HPV DNA testing and cytology are presented in Table. Of the 5 patients diagnosed with CIN and CIN 3, 37 pa- Arch Pathol Lab Med Vol 8, March 4 HPV DNA Testing for Cervical Lesions Lee et al 99
3 Figure. Age distribution of patients with positive test results. The percentage of abnormal results using conventional cytology shows gradual increase according to age, whereas positive results using human papillomavirus DNA testing are associated with higher percentages at age ranges (younger than 3 years and older than 6 years). tients (9.7%) were HPV positive, 6 patients (76.8%) were proven to have abnormal cytology, and 47 patients (97.6%) had positive results from either HPV DNA testing or cytology. The sensitivity values for invasive cervical cancer detection using HPV DNA testing and cytology were 97.9% (46/47) and 74.5% (35/47), respectively. The combination of both tests yielded a % (47/47) sensitivity for invasive cervical cancer detection. Table demonstrates that HPV DNA testing was more sensitive than cytology in detecting high-grade cervical lesions, especially for cervical cancer detection. Not a single case of invasive cervical cancer was missed with the use of HPV DNA testing in conjunction with cytology. The greater sensitivity in detecting cervical lesions depended on the patient s age. The age distribution of patients with positive tests is illustrated in Figure. The peak prevalence age for abnormal tests was between 3 and 59 years. The percentage of abnormal results by conventional cytology showed gradual increase according to age, and positive results of HPV DNA testing had higher percentages in age ranges (younger than 3 and older than 6 years) than in other age ranges. Interestingly, there was a maximal 6% positive rate difference between HPV DNA testing and cytology in patients younger than 3 years, and these differences decreased according to an increase in age. Figure shows that HPV DNA testing proved to be more sensitive than cytology for patients between 3 and 59 years (P.). In a group of women older than 6 years, a higher detection rate of HPV infection was observed in CIN or higher lesions. The data in our tables and figures demonstrate a high sensitivity rate with HPV DNA testing for the detection of high-grade cervical lesions for all ages. The greater sensitivity for the HPV DNA testing compared to conventional cytology was also discovered within each age group. COMMENT Genital tract infection with HPV is the most common sexually transmitted viral disease among young adults who are sexually active with multiple partners. 5 Most HPV infections can be cleared spontaneously within a few months (mean duration, 8 4 months), especially in young women. 6,7 However, occasionally cervical epithelial changes take place that can progress into intraepithelial neoplasia, carcinoma in situ, or invasive cancer. 8,9 Depending on the degree and thickness of epithelial involvement, these changes can be classified as either low- or high-grade lesions. The evolving etiologic role of the HPV infection in cervical carcinogenesis and advances in technologies for HPV detection are of central concern. Currently, the Pap test is the method of choice for mass screening and has been used for the early detection of cervical lesions since the mid 95s. However, this method has a high false-negative rate (5% 45%) in detecting cancer precursors, and falsepositive rates of 5% to 5% have increased gynecologic referrals and are a cause of patient anxiety.,3,4 This method also has poor reproducibility, interpretation of results is subjective, and it carries a high probability for misclassification. 5 In addition to technical advances, an improved sampling procedure, as used in the ThinPrep test, has been introduced. This procedure provides a single specimen that is appropriate for both cytology and HPV DNA testing, and it also shows increased sensitivity for abnormalities in many studies. 6 9 Several studies have implied that organized screening programs are a superior method in achieving a high population coverage and reduction of cervical cancer mortality rates. 3 Recent studies present this with relation to HPV DNA testing in conjunction with cytology and in terms of the age of women. 9 The dominant age group with the highest HPV prevalence involves 3 Arch Pathol Lab Med Vol 8, March 4 HPV DNA Testing for Cervical Lesions Lee et al
4 Figure. The sensitivity of each test. Human papillomavirus DNA testing proved to be more sensitive than cytology for patients between the ages of 3 and 59 years (P.). women younger than 5 years; prevalence is much lower in women older than 6 years, 3 33 but the incidence of high-grade cervical lesions rises along with age. 34 Persistent rather than transient HPV infection may lead to cervical precancerous lesions or cancers. 9 Therefore, many authors have recommended the use of HPV DNA testing for women older than 3 years Our study shows a higher number of abnormal HPV DNA test results in the group aged between 3 and 59 years old with high-grade cervical lesions. New guidelines published by the American Cancer Society in November recommended consideration of the combination of HPV DNA testing for high-risk HPV types, together with a Pap test, as a primary cervical cancer screening approach. 39,4 Several authors have presented cervical cancer screening algorithms for developing countries, which include the screening combination of HPV and Pap tests biennially or every several years to prevent the progression of precancerous lesions or cancer at a reasonable time compared to the Pap test alone. 9,4 44 Furthermore, HPV DNA testing can be performed with material collected at the time the smear is taken without additional discomfort for the women being screened. Additionally, in an attempt to reduce the incidence and mortality rates of cervical cancer, HPV DNA testing may also improve test efficiency and reduce screening costs. 9,39 For example, physicians will be able to immediately refer women who have persistent lesions, and the combined approach may allow longer intervals between screening tests for women in younger age groups who truly test negative for both tests. We know that positive results for HPV can predict an increased likelihood of histologically confirmed CIN, taking the severity of a concurrent cytologic diagnosis into account. Results of this study suggest that HPV DNA testing is very useful and valuable in providing an opportunity to improve detection of high-grade cervical lesions according to age. Moreover, using a combination of HPV DNA testing and cytology increases efficiency in the detection of cervical lesions and may contribute to the patient s reassurance and comfort. Therefore, HPV DNA testing can be highly recommended as a substitute method for detecting high-grade cervical lesions, especially for invasive cervical cancer. Further improvement of sensitivity in the screening of cervical lesions can be achieved by using conventional cytology and HPV DNA testing together. Combining the tests will prove beneficial in the detection of cancer precursors in older women. We thank the medical personnel at the Clinical Laboratory and Pathology Department, Korea University, Guro Hospital, Seoul, for helping us prepare this article. Many thanks also go to the participants in this study and to Jin-ho Yoo, MS, at ISTECH Inc, Korea, for statistical consultations. References. Kim SJ, Park CK, Lee HP, Namkoong SE, Kang SB, Saw HS. Multiinstitutional study for the development of cervical cancer screening model with new cervicography, PAP smear and HPV DNA test. Korean J Obstet Gynecol. ;44: Koss LG. The Papanicolaou test for cervical cancer detection: a triumph and a tragedy. JAMA. 989;6: Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade or 3 in relation to papillomavirus infection. N Engl J Med. 99;37: Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smear as a predictor of high grade cervical intraepithelial neoplasia. Br J Cancer. 994;69: Gaarenstroom KN, Melkert P, Walboomers JM, et al. Human papillomavirus DNA genotypes: prognostic factors for progression of cervical intraepithelial neoplasia. Int J Gynecol Cancer. 994;4: Kjaer SK, van den Brule AJ, Bock JE, et al. Human papillomavirus: the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer. 996;65: Lorinicz AT, Reid R, Jenson AB, Greegberg MD, Lancaster W, Kurman RJ. Human papillomavirus infection of cervix: relative risk association of 5 common anogenital types. Obstet Gynecol. 99;79: Franco EL, Ferenczy A. Assessing gains in diagnostic utility when human papillomavirus testing is used as an adjunct to Papanicolaou smear in the triage Arch Pathol Lab Med Vol 8, March 4 HPV DNA Testing for Cervical Lesions Lee et al 3
5 of women with cervical cytologic abnormalities. Am J Obstet Gynecol. 999; 8: Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesion: a study of 793 women. Br J Cancer. ;84: Bishop JW, Hartinger JS, Pawlick GF. Time interval effect on repeat cervical smear results. Acta Cytol. 997;4: Ronnett BM, Manos MM, Ransley JE, et al. Atypical glandular cells of undetermined significance (AGUS): cytopathologic features, histopathologic results, and HPV DNA detection. Hum Pathol. 999;3: Manos MM, Kinney WK, Hurley LB, et al. Identifying women with cervical neoplasia using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA. 999;8: Kadish AS, Timmins P, Wang Y, et al. Regression of intracervical neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 6 E7 peptide. Cancer Epidemiol Biomarkers Prev. ;: Kiviat NB, Koutsky LA. Do our current cervical cancer control strategies still make sense? J Natl Cancer Inst. 996;88: Swygart C. Human papillomavirus: disease and laboratory diagnosis. Br J Biomed Sci. 997;54: Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 998; 338: Franco EL, Villa LL, Sobrinho JP, et al. Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from high risk area for cervical cancer. J Infect Dis. 999;8: Burk RD. Pernicious papillomavirus infection. N Engl J Med. 999;34: Wallin KL, Wiklund F, Angstrom T, et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med. 999;34: Ho GY, Burk RD, Klein S, et al. Persistent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer Inst. 995; 87: Remmink AJ, Walboomers JM, Helmerhorst TJ, et al. The presence of persistent high risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer. 995;6: Johnston C. Quantitative tests for human papillomavirus. Lancet. ; 355: Lee KR, Manna EA, St John T. Atypical endocervical glandular cells: accuracy of cytologic diagnosis. Diagn Cytopathol. 995;3: Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 6 and risk of cervical carcinoma in situ: a nested casecontrol study. Lancet. ;355: Stoler MH, Schiffman M. Interobserver reproducibility of cervical cytologic and histologic interpretation: realistic estimates from the ASCUS-LSIL triage study. JAMA. ;85: Lee KR, Ashfaq R, Birdsong GG, Corkill ME, McIntosh KM, Inhorn SL. Comparison of conventional Papanicolaou smears and a fluid based, thin layer system for cervical cancer screening. Obstet Gynecol. 997;9: Robert LM, Gurley AM, Thurloe JK, Bowditch R, Laverty CRA. Evaluation of the ThinPrep Pap test as an adjunct to the conventional Pap smear. Med J Aust. 997;67: Papillo JL, Zarka MA, St John TL. Evaluation of the ThinPrep Pap test in clinical practice: a seven month, 6,34 case experience in northern Vermont. Acta Cytol. 998;4: Dupree WB, Suprun HZ, Beckwith DG, Shane JJ, Lucente V. The promise and risk of a new technology: the Lehigh Valley Hospital s experience with liquidbased cervical cytology. Cancer. 998;84: Hakama M, Chamberlain J, Day NE, Miller AB, Prorok PC. Evaluation of screening programmes for gynaecological cancer. Br J Cancer. 985;5: Morrison EAB, Ho GYF, Vermund SH, et al. Human papillomavirus infection and other risk factors for cervical neoplasia: a case control study. Int J Cancer. 99;49: Schiffman MH. Epidemiology of cervical human papillomavirus infections. Curr Top Microbiol Immunol. 994;86: Meijer CJLM, van den Brule AJC, Snijders PJF, Helmerhorst T, Kenemans P, Wallbumers JMM. Detection of human papillomavirus in cervical scrapes by the polymerase chain reaction in relation to cytology: possible implications for cervical cancer screening. IARC Monogr Eval Carcinog Risks Hum. 99;9: Melkert PW, Hopman E, van den Brule AJ, et al. Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer. 993;53: Wright TC Jr, Lorincz AT, Ferris DG, et al. Reflex human papillomavirus deoxyribonucleic acid testing in women with abnormal Papanicolaou smear. Am J Obstet Gynecol. 998;78: Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. Br J Cancer. 999;8: Stoler M. Advances in cervical screening technology. Mod Pathol. ; 3: Cuzick J, Sasieni P, Davies P, et al. A systemic review of the role of human papillomavirus (HPV) testing within a cervical screening programme: summary and conclusions. Br J Cancer. ;83: Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. ;5: American Cancer Society. Cancer facts and figures 3. Available at: 4. Mandelbaltt JS, Lawrence WF, Womack SM, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. ;87: Belinson J, Qiao YL, Pretorius R, et al. Shanxi Province cervical cancer screening study: a cross-sectional comparative trial of multiple techniques to detect cervical neoplasia. Gynecol Oncol. ;83: Jeanne SM, William FL, Sharita MW, et al. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA. ;87: Cuzick J, Sasieni P. Estimates of the cost impact of introducing human papillomavirus testing into a cervical screening programme. In: Franco E, Monsonego J, eds. New Developments of Cervical Cancer Screening and Prevention. Oxford, United Kingdom: Blackwell Scientific Publications, Ltd; 997: Arch Pathol Lab Med Vol 8, March 4 HPV DNA Testing for Cervical Lesions Lee et al
The Korean Journal of Cytopathology 15 (1) : 17-27, 2004
5 The Korean Journal of Cytopathology 5 () : 7-7, / 5 / / (human papillomavirus, HPV), 6%, 5% HPV. HPV HPV. HPV HPV,,5 HPV HPV. HPV, 6 HPV. HPV HPV International Agency for Research on Cancer (IARC) HPV
More informationCervical cytology screening has led to a reduction in cancer mortality
CANCER CYTOPATHOLOGY 105 ThinPrep Pap Test Performance and Biopsy Follow-Up in a University Hospital A. Betts Carpenter, M.D., Ph.D. Diane D. Davey, M.D. Department of Pathology and Laboratory Medicine,
More informationAtypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing
Anatomic Pathology / ATYPICAL GLANDULAR CELLS AND HUMAN PAPILLOMAVIRUS Atypical Glandular Cells of Undetermined Significance Outcome Predictions Based on Human Papillomavirus Testing Jeffrey F. Krane,
More informationNews. Laboratory NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING TIMOTHY UPHOFF, PHD, DABMG, MLS (ASCP) CM
Laboratory News Inside This Issue NEW GUIDELINES DEMONSTRATE GREATER ROLE FOR HPV TESTING IN CERVICAL CANCER SCREENING...1 NEW HPV TEST METHODOLOGY PROVIDES BETTER SPECIFICITY FOR CERVICAL CANCER...4 BEYOND
More informationA systematic review of the role of human papilloma virus (HPV) testing within a cervical screening programme: summary and conclusions
British Journal of Cancer (2000) 83(5), 561 565 doi: 10.1054/ bjoc.2000.1375, available online at http://www.idealibrary.com on A systematic review of the role of human papilloma virus (HPV) testing within
More informationAtypical squamous cells. The case for HPV testing
OBG MANAGEMENT FOCUS ON CERVICAL DISEASE BY J. THOMAS COX, MD ASC-US is most often due to transient changes or HPV. HPV-positive ASC-US is 12.5 to 23 times more likely to be associated with CIN 2,3 on
More informationHPV Testing & Cervical Cancer Screening:
HPV Testing & Cervical Cancer Screening: Are they linked? By William Chapman, MD, FRCPC Screening for precursor lesions of cervical cancer by the Papanicolaou (Pap) smear has been one of the greatest success
More informationFor the Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study Group
Effects of Age and Human Papilloma Viral Load on Colposcopy Triage: Data From the Randomized Atypical Squamous Cells of Undetermined Significance/ Low-Grade Squamous Intraepithelial Lesion Triage Study
More informationHPV Genotyping: A New Dimension in Cervical Cancer Screening Tests
HPV Genotyping: A New Dimension in Cervical Cancer Screening Tests Lee P. Shulman MD The Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief, Division of Clinical Genetics Feinberg School
More informationThe Korean Journal of Cytopathology 13(1): 14-20, 2002
13 1 The Korean Journal of Cytopathology 13(1): 14-20, 2002 : ASCUS 1941 Papanicolaou. The Bethesda System(TBS) 1) 1988, atypical squamous cells of undetermined significance(ascus), low-grade squamous
More informationComparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic biopsy
Iranian Journal of Reproductive Medicine Vol.5. No.3. pp:121-126, Summer 2007 Comparative study of human papilloma virus DNA detection and results of histopathological examination of cervical colposcopic
More informationNo HPV High Risk Screening with Genotyping. CPT Code: If Result is NOT DETECTED (x3) If Results is DETECTED (Genotype reported)
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 117 August 6, 2013 HPV High Risk Screening with Genotyping Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Director, Molecular Pathology
More informationPAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE
Arch Iranian Med 2005; 8 (3): 192 196 Original Article PAP SMEAR WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Fatemeh Ghaemmaghami MD *, Fereshteh Ensani MD**, Nadereh Behtash MD* Ebrahim
More informationCytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches.
Cytology/Biopsy/Leep Gynecologic Correlation: Practical Considerations and Approaches. Fadi W. Abdul-Karim MD MEd. Professor of Pathology. Vice chair for education. Robert Tomsich Pathology and Lab Med
More informationAppropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines
Appropriate Use of Cytology and HPV Testing in the New Cervical Cancer Screening Guidelines Tim Kremer, MD Ralph Anderson, MD 1 Objectives Describe the natural history of HPV particularly as it relates
More informationThe devil is in the details
The cobas KNOW THE RISK For cervical cancer prevention The devil is in the details Leading with the cobas as your primary screening method uncovers disease missed by cytology, and can protect women from
More informationChapter 14: Role of Triage Testing in Cervical Cancer Screening
Chapter 14: Role of Triage Testing in Cervical Cancer Screening Diane Solomon The classic model of cervical cancer prevention primary screening with cytology, followed by diagnostic colposcopically directed
More informationOriginal Policy Date
MP 2.04.03 Cervicography Medical Policy Section Medicine Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013 Return to Medical Policy Index Disclaimer
More informationDevelopment and Duration of Human Papillomavirus Lesions, after Initial Infection
MAJOR ARTICLE Development and Duration of Human Papillomavirus Lesions, after Initial Infection Rachel L. Winer, 1 Nancy B. Kiviat, 2 James P. Hughes, 3 Diane E. Adam, 1 Shu-Kuang Lee, 3 Jane M. Kuypers,
More informationNegative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
Anatomic Pathology / FALSE-NEGATIVE HISTOLOGIC FINDINGS Negative Colposcopic Biopsy After Positive Human Papilloma Virus (HPV) DNA Testing False-Positive HPV Results or False-Negative Histologic Findings?
More informationWoo Dae Kang, Ho Sun Choi, Seok Mo Kim
Is vaccination with quadrivalent HPV vaccine after Loop Electrosurgical Excision Procedure effective in preventing recurrence in patients with High-grade Cervical Intraepithelial Neoplasia (CIN2-3)? Chonnam
More informationVasile Goldiş Western University of Arad, Faculty of Medicine, Obstetrics- Gynecology Department, Romania b
Mædica - a Journal of Clinical Medicine ORIGINAL PAPERS Cervical Intraepithelial Neoplasia in the Dr. Salvator Vuia Clinical Obstetrics and Gynecology Hospital - Arad During the 2000-2009 Period Voicu
More informationEfficiency of the Hybrid Capture 2 HPV DNA Test in Cervical Cancer Screening A Study by the French Society of Clinical Cytology
Anatomic Pathology / HPV DNA TEST IN CERVICAL CANCER SCREENING Efficiency of the Hybrid Capture 2 HPV DNA Test in Cervical Cancer Screening A Study by the French Society of Clinical Cytology Patricia de
More informationHPV-DNA Test Kit in Cervical Scrapes or
Infectious Diseases in Obstetrics and Gynecology 2:126-129 (I 994) (C) 1994 Wiley-Liss, Inc. Detection of Human Papillomavirus DNA by AffiProbe HPV-DNA Test Kit in Cervical Scrapes or Biopsies-Histopathologic
More informationBiomed Environ Sci, 2015; 28(1): 80-84
80 Biomed Environ Sci, 2015; 28(1): 80-84 Letter to the Editor Assessing the Effectiveness of a Cervical Cancer Screening Program in a Hospital-based Study* YANG Yi1, LANG Jing He1, WANG You Fang1, CHENG
More informationHuman papillomavirus typing in HIV-positive women
Infect Dis Obstet Gynecol ;9:89 93 Human papillomavirus typing in HIV-positive women Meera Hameed, Helen Fernandes, Joan Skurnick, Dorothy Moore, Patricia Kloser 3 and Debra Heller Department of Pathology
More informationHigh-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics, and Clinical Meaning for Cervical Cancer
103 Ivyspring International Publisher Research Paper International Journal of Medical Sciences 2012; 9(1):103-107 High-risk Human Papillomavirus Infection in Low Risk Women: Incidence, Patient Characteristics,
More informationA Cytologic/Histologic Review of 367 Cases. Original Article. Cancer Cytopathology August 25,
Correlation Between Hybrid Capture II High-Risk Human Papillomavirus DNA Test Chemiluminescence Intensity From Cervical Samples With Follow-Up Histologic Results A Cytologic/Histologic Review of 367 Cases
More informationHUMAN PAPILLOMAVIRUS TESTING
CLINICAL GUIDELINES For use with the UnitedHealthcare Laboratory Benefit Management Program, administered by BeaconLBS HUMAN PAPILLOMAVIRUS TESTING Policy Number: PDS - 016 Effective Date: October 1, 2018
More informationHuman Papillomavirus Testing Using Hybrid Capture II With SurePath Collection
468 Human Papillomavirus Testing Using Hybrid Capture II With SurePath Collection Initial Evaluation and Longitudinal Data Provide Clinical Validation for This Method Vincent Ko, MD Rosemary H. Tambouret,
More informationComparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer
BJOG: an International Journal of Obstetrics and Gynaecology August 2004, Vol. 111, pp. 842 848 DOI: 1 0. 1111/j.1471-0528.2004.00210.x Comparison of HPV test versus conventional and automation-assisted
More informationNatural History of HPV Infections 15/06/2015. Squamous cell carcinoma Adenocarcinoma
14,670 5796 United States/ Canada 17,165 8124 Central America 48,328 21,402 South America 59,929 29,814 Europe 78,896 61,670 Africa 157,759 86,708 Southcentral Asia 61,132 31,314 Eastern Asia 42,538 22,594
More informationNHSCSP proposals for cervical screening intervals. Comments and recommendations of Council of the British Society for Clinical Cytology
NHSCSP proposals for cervical screening intervals Comments and recommendations of Council of the British Society for Clinical Cytology The following paper is written on behalf of BSCC Council to express
More informationCan HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation?
Anatomic Pathology / Monitoring HPV-16 Fractions in CIN Can HPV-16 Genotyping Provide a Benchmark for Cervical Biopsy Specimen Interpretation? Mary T. Galgano, MD, 1 Philip E. Castle, PhD, MPH, 2 Mark
More informationPapers. Abstract. Introduction. Methods
Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study Susanne
More informationLessons From Cases of Screened Women Who Developed Cervical Carcinoma
Lessons From Cases of Screened Women Who Developed Cervical Carcinoma R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center raustin@magee.edu Why Focus Study On Cases
More informationCervical Cancer Screening. David Quinlan December 2013
Cervical Cancer Screening David Quinlan December 2013 Cervix Cervical Cancer Screening Modest variation provincially WHO and UK begin at 25 stop at 60 Finland begin at 30 stop at 60 Rationale for
More informationCervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines. June 2013
Cervical Cancer Screening for the Primary Care Physician for Average Risk Individuals Clinical Practice Guidelines General Principles: Since its introduction in 1943, Papanicolaou (Pap) smear is widely
More informationNegative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions
British Journal of Cancer (2004) 90, 1803 1808 All rights reserved 0007 0920/04 $25.00 www.bjcancer.com Negative human papillomavirus testing in normal smears selects a population at low risk for developing
More informationHPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options
HPV-Negative Results in Women Developing Cervical Cancer: Implications for Cervical Screening Options R. Marshall Austin MD,PhD Magee-Womens Hospital of University of Pittsburgh Medical Center (UPMC) (raustin@magee.edu)
More informationAbnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing
280 Abnormal Cervicovaginal Cytology With Negative Human Papillomavirus Testing Giovanni Negri, MD Bettina Rigo, BS Fabio Vittadello, ScD Christine Mian, ScD Eduard Egarter-Vigl, MD Department of Pathology,
More informationCytologic screening programs to detect cervical intraepithelial
Combining Human Papillomavirus Testing or Cervicography With Cytology to Detect Cervical Neoplasia Michelle Howard, MSc; John W. Sellors, MD, MSc; Alice Lytwyn, MD, MSc; Paula Roth, MD; James B. Mahony,
More informationMaking Sense of Cervical Cancer Screening
Making Sense of Cervical Cancer Screening New Guidelines published November 2012 Tammie Koehler DO, FACOG The incidence of cervical cancer in the US has decreased more than 50% in the past 30 years because
More informationAcceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index
DOI 10.1007/s00404-012-2569-y GYNECOLOGIC ONCOLOGY Acceptable predictive accuracy of histopathology results by colposcopy done by Gynecology residents using Reid index Hadi Shojaei Fariba Yarandi Leila
More informationCervical Precancer: Evaluation and Management
TAJ June 2002; Volume 15 Number 1 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Review fam Cervical Precancer: Evaluation and Management SM Khodeza Nahar Begum 1 Abstract Carcinoma of
More informationAssociate Professor of Gyn. & Obs., Department of Gynecology and Obstetrics, Tehran University of Medical Sciences, Iran.
Assessment of Visual Inspection with Acetic Acid (VIA) as a Screening Test for Cervical Neoplasia in Comparison with Cytologic Screening in Imam Khomeini Hospital F. Ghaemmaghami, MD Associate Professor
More informationCervical cancer prevention: Advances in primary screening and triage system
Cervical cancer prevention: Advances in primary screening and triage system Dr Farid Hadi Regional Medical and Scientific Affairs Roche Diagnostics Asia-Pacific, Singapore Cervical cancer is highly preventable
More informationDepartment of Pathology, Kathmandu Medical College & Teaching Hospital, Sinamangal, Kathmandu, Nepal
Kathmandu University Medical Journal (2007), Vol. 5, No. 4, Issue 20, 461-467 Original Article Correlation of PAP smear findings with clinical findings and cervical biopsy Pradhan B 1, Pradhan SB 2, Mital
More informationOutcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure
The Korean Journal of Pathology 2012; 46: 359-364 ORIGINAL ARTICLE Outcome of Atypical Squamous Cells in Cervical Cytology: Follow-up Assessment by Loop Electrical Excision Procedure Joon Seon Song Ilseon
More informationCervical Cancer Screening
Todd R. Jenkins, MD, MSHA Senior Vice Chair Director, Division of Women s Reproductive Healthcare Learning Objectives Describe the etiology, natural history, and usage of the human papillomavirus (HPV)
More informationComparative evaluation of smear cytology & hybrid capture II for the diagnosis of cervical cancer
Indian J Med Res 126, July 2007, pp 39-44 Comparative evaluation of smear cytology & hybrid capture II for the diagnosis of cervical cancer Kamlesh Kumar, Venkateswaran K. Iyer, Neerja Bhatla*, Alka Kriplani*
More informationPrior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory
Prior High-Risk HPV Testing and Pap Test Results for 427 Invasive Cervical Cancers in China s Largest CAP-Certified Laboratory Baowen Zheng, MD 1 ; Zaibo Li, MD, PhD 2 ; Christopher C. Griffith, MD, PhD
More informationCan LBC Completely Replace Conventional Pap Smear in Developing Countries
The Journal of Obstetrics and Gynecology of India (January February 2019) 69(1):69 76 https://doi.org/10.1007/s13224-018-1-7 ORIGINAL ARTICLE Can LBC Completely Replace Conventional Pap Smear in Developing
More informationCAP Laboratory Improvement Programs
CAP Laboratory Improvement Programs Comparison of Performance of Conventional and ThinPrep Gynecologic Preparations in the College of American Pathologists Gynecologic Cytology Program Andrew A. Renshaw,
More informationRESEARCH ARTICLE. Abstract. Introduction
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.16.6857 Cost-Effectiveness of Strategies for Detection CIN2+ in Women with ASC-US Pap Smears in Thailand RESEARCH ARTICLE Cost-Effectiveness Analysis of Different
More informationIN THE UNITED STATES, CYTOLOGIcal
ORIGINAL CONTRIBUTION Cost-effectiveness of Alternative Triage Strategies for Atypical Squamous Cells of Undetermined Significance Jane J. Kim, MS Thomas C. Wright, MD Sue J. Goldie, MD, MPH IN THE UNITED
More informationUnderstanding Your Pap Test Results
Understanding Your Pap Test Results Most laboratories in the United States use a standard set of terms called the Bethesda System to report pap test results. Normal: Pap samples that have no cell abnormalities
More informationPerformance of the Aptima High-Risk Human Papillomavirus mrna Assay in a Referral Population in Comparison with Hybrid Capture 2 and Cytology
JOURNAL OF CLINICAL MICROBIOLOGY, Mar. 2011, p. 1071 1076 Vol. 49, No. 3 0095-1137/11/$12.00 doi:10.1128/jcm.01674-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. Performance
More informationLong-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance
Anatomic Pathology / LONG-TERM OUTCOME WITH ATYPICAL SQUAMOUS CELLS OF UNDETERMINED SIGNIFICANCE Long-Term Outcome and Relative Risk in Women With Atypical Squamous Cells of Undetermined Significance Stephen
More informationFaculty Pap Smear Guidelines: Family Planning Update 2008 Part Two
Faculty Pap Smear Guidelines: Family Planning Update 2008 Part Two Seshu P. Sarma, MD, FAAP Emory University Regional Training Center Atlanta, Georgia Produced by the Alabama Department of Public Health
More informationGUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED
GUIDELINE FOR SCREENING FOR CERVICAL CANCER: REVISED This guideline is a revised version of the guideline developed in February 2000, by the Cervical Cancer Screening Working Group. This revised version
More informationHuman Papillomavirus Prevalence and Type Distribution Among 968 Women in South Korea
JOURNAL OF CANCER PREVENTION Vol. 21, No. 2, June 2016 http://crossmark.crossref.org/dialog/?doi=10.15430/jcp.2016.21.2.104&domain=pdf&date_stamp=2016-6-30 http://dx.doi.org/10.15430/jcp.2016.21.2.104
More informationHuman Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer
original article Human Papillomavirus and Papanicolaou Tests to Screen for Cervical Cancer Pontus Naucler, M.D., Ph.D., Walter Ryd, M.D., Sven Törnberg, M.D., Ph.D., Anders Strand, M.D., Ph.D., Göran Wadell,
More informationHuman Papillomavirus
Human Papillomavirus Dawn Palaszewski, MD Assistant Professor of Obstetrics and Gynecology University of February 18, 2018 9:40 am Dawn Palaszewski, MD Assistant Professor Department of Obstetrics and
More informationHPV Testing ASC-US. Jodie Zeke, a nurse practitioner, received initial CE2. 5. By Kim K. Choma, MSN, APN,C
CE2. 5 HOURS Continuing Education By Kim K. Choma, MSN, APN,C & ASC-US HPV Testing When the Pap result is atypical squamous cells of undetermined significance, testing for the human papillomavirus may
More informationUtilization of the Biomarkers to Improve Cervical Cancer Screening
Utilization of the Biomarkers to Improve Cervical Cancer Screening Elena BERNAD Victor Babes University of Medicine and Pharmacy Timisoara, Romania Cervical cancer is at the second most common cancer in
More informationPrevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea
RESEARCH COMMUNICATION Prevalence and Determinants of High-risk Human Papillomavirus Infection in Women with High Socioeconomic Status in Seoul, Republic of Korea Kidong Kim 1, Jin Ju Kim 2,3, Sun Mie
More informationThe comparative diagnostic accuracy of conventional and liquid-based cytology in a colposcopic setting
BJOG: an International Journal of Obstetrics and Gynaecology November 2005, Vol. 112, pp. 1542 1546 DOI: 10.1111/j.1471-0528.2005.00699.x The comparative diagnostic accuracy of conventional and liquid-based
More informationCervical Screening Results Leading to Detection of Adenocarcinoma in Situ of the Uterine Cervix
DOI:10.31557/APJCP.2019.20.2.377 Cervical Screening Results Leading to Detecting Cervical AIS RESEARCH ARTICLE Editorial Process: Submission:09/27/2018 Acceptance:01/18/2019 Cervical Screening Results
More informationEdinburgh Research Explorer
Edinburgh Research Explorer Persistent high risk HPV infection associated with development of cervical neoplasia in a prospective population study Citation for published version: Cuschieri, K, Cubie, H,
More informationVery Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests
292 Very Low Human Papillomavirus DNA Prevalence in Mature Women With Negative Computer-Imaged Liquid-Based Pap Tests Chengquan Zhao, MD 1 Esther Elishaev, MD 1 Ke-Hai Yuan, PhD 2 Jing Yu, MD 1 R. Marshall
More informationObjectives. I have no financial interests in any product I will discuss today. Cervical Cancer Screening Guidelines: Updates and Controversies
Cervical Cancer Screening Guidelines: Updates and Controversies I have no financial interests in any product I will discuss today. Jody Steinauer, MD, MAS University of California, San Francisco Objectives
More informationHPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe. Mark H. Stoler, MD ASC Companion Meeting USCAP 2008
OBJECTIVES: HPV TESTING AND UNDERSTANDING VALIDITY: A tough row to hoe Mark H. Stoler, MD ASC Companion Meeting USCAP 2008 1. Describe the concept of marker validation in the context of HPV tests. 2. Present
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 341 N OVEMBER 25, 1999 NUMBER 22 TYPE-SPECIFIC PERSISTENCE OF HUMAN PAPILLOMAVIRUS DNA BEFORE THE DEVELOPMENT
More informationIMPLEMENTATION OF CYTOLOGIC
ORIGINAL CONTRIBUTION HPV DNA Testing of Self-collected Vaginal Samples Compared With Cytologic Screening to Detect Cervical Cancer Thomas C. Wright, Jr, MD Lynette Denny, MMED, FCOG Louise Kuhn, PhD Amy
More informationCONCERN ABOUT THE LOW SENsitivity
ORIGINAL CONTRIBUTION Evaluation of Human Papillomavirus Testing in Primary Screening for Cervical Abnormalities Comparison of Sensitivity, Specificity, and Frequency of Referral Shalini L. Kulasingam,
More informationHuman Papillomaviruses and Cancer: Questions and Answers. Key Points. 1. What are human papillomaviruses, and how are they transmitted?
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Human Papillomaviruses
More informationProfile Of Cervical Smears Cytology In Western Region Of Saudi Arabia
ISPUB.COM The Internet Journal of Gynecology and Obstetrics Volume 1 Number 2 Profile Of Cervical Smears Cytology In Western Region Of Saudi Arabia I Mansoor Citation I Mansoor. Profile Of Cervical Smears
More informationThe Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal Women Over a 10-Year Period
Published Online First on October 23, 2006 as 10.1158/0008-5472.CAN-06-1057 Research Article The Absolute Risk of Cervical Abnormalities in High-risk Human Papillomavirus Positive, Cytologically Normal
More informationPAP smear. (Papanicolaou Test)
PAP smear (Papanicolaou Test) Is a screening test to prevent/ detect cancerous processes in endocervical canal It reduces the mortality caused by cervical cancer up to 80% M. Arbyn; et al. (2010). "European
More informationBRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM
BRITISH COLUMBIA S CERVICAL CANCER SCREENING PROGRAM DATE: NOVEMBER 19, 2016 PRESENTER: DR. DIRK VAN NIEKERK 1 Conflict of Interest Disclosure Nothing to disclose 2 ..in the beginning of the malady it
More informationANALYSES OF CERVICAL CANCER IN RAJKOT POPULATION
Electronic Journal of Pharmacology and Therapy Vol 4, 15-20 (2011) ISSN: 0973-9890 (Available online at wwwtcrjournalscom) Clinical Article ndexed in: ProQuest database Abstract, USA (ProQuest Science
More informationBC Cancer Cervix Screening 2015 Program Results. February 2018
BC Cancer Cervix Screening 2015 Program Results BC Cancer Cervix Screening 2015 Program Results 2 Table of Contents BC Cancer Cervix Screening 2015 Program Results... 1 Table of Contents... 2 Program Overview...
More informationCervical Screening for Dysplasia and Cancer in Patients with HIV
Cervical Screening for Dysplasia and Cancer in Patients with HIV Adult Clinical Guideline from the New York State Department of Health AIDS Institute w w w.hivg uidelines.org Purpose of the Guideline Increase
More informationComparison between Siriraj Liquid-based and Conventional Cytology for Detection of Abnormal Cervicovaginal Smears: A Split-sample Study
Comparison between Liquid-based and Conventional Cytology in Thailand RESEARCH COMMUNICATION Comparison between Siriraj Liquid-based and Conventional Cytology for Detection of Abnormal Cervicovaginal Smears:
More informationIn 1988, The Bethesda System (TBS) introduced the phrase atypical
CANCER CYTOPATHOLOGY 93 Should the Cytologic Diagnosis of Atypical Squamous Cells of Undetermined Significance Be Qualified? An Assessment Including Comparison between Conventional and Liquid-Based Technologies
More informationInternational Journal of Biological & Medical Research
Int J Biol Med Res. ; 2(3): 757-761 Int J Biol Med Res www.biomedscidirect.com Volume 2, Issue 3, July BioMedSciDirect Publications Contents lists available at BioMedSciDirect Publications International
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Prevention: 2012 and Beyond George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics University of California,
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationHPV AND CERVICAL CANCER
HPV AND CERVICAL CANCER DR SANDJONG TIECHOU ISAAC DELON Postgraduate Training in Reproductive Health Research Faculty of Medicine, University of Yaoundé 2007 INTRODUCTION CERVICAL CANCER IS THE SECOND
More informationColposcopy at a crossroads
American Journal of Obstetrics and Gynecology (2006) 195, 349 53 www.ajog.org CLINICAL OPINION Colposcopy at a crossroads Jose Jeronimo, MD, Mark Schiffman, MD, MPH Hormonal and Reproductive Epidemiology
More informationCervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients
Cervical FISH Testing for Triage and Support of Challenging Diagnoses: A Case Study of 2 Patients Richard Hopley, MD, Alexandra Gillespie, MD* Laboratory Medicine 47:1:52-56 CLINICAL HISTORY Patients:
More informationHuman papiloma virus testing in the cervix of high-risk women: A hospital-based clinicopathological, colposcopic, and cytogenetic study
Research Article Human papiloma virus testing in the cervix of high-risk women: A hospital-based clinicopathological, colposcopic, and cytogenetic study Subhash Bhardwaj 1, Farooq Ahmed Wani 2, Altaf Bandy
More informationCervical Cancer 4/27/2016
Guidelines for Cervical Cancer Screening and Prevention Management of Abnormal Results Kathy A. King, MD Assistant Professor of OB/GYN Medical College of Wisconsin May 6, 2016 Cervical Cancer In US about
More informationEvaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions on Cervical Smear
The Korean Journal of Pathology 2010; 44: 528-35 DOI: 10.4132/KoreanJPathol.2010.44.5.528 Evaluation of Low-Grade Squamous Intraepithelial Lesions, Cannot Exclude High-Grade Squamous Intraepithelial Lesions
More informationNew cervical cancer screening strategy: Combined Pap and HPV testing
REVIEW CME CREDIT XIAN WEN JIN, MD, PhD Department of General Internal Medicine, The Cleveland Clinic Foundation KRISTINE ZANOTTI, MD Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation
More informationI have no financial interests in any product I will discuss today.
Cervical Cancer Screening Update and Implications for Annual Exams George F. Sawaya, MD Professor Department of Obstetrics, Gynecology and Reproductive Sciences Department of Epidemiology and Biostatistics
More informationPhilip E. Castle, Diane Solomon, Mark Schiffman, Cosette M. Wheeler for the ALTS Group
ARTICLEARTICLESHuman Papillomavirus Type 16 Infections and 2-Year Absolute Risk of Cervical Precancer in Women With Equivocal or Mild Cytologic Abnormalities Philip E. Castle, Diane Solomon, Mark Schiffman,
More informationResearch Recherche. Return to September 5, 2000 Table of Contents
Comparison of self-collected vaginal, vulvar and urine samples with physician-collected cervical samples for human papillomavirus testing to detect high-grade squamous intraepithelial lesions John W. Sellors,
More information